Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

⚕️ “If you want to understand the health of a population, look at the air they breathe, the water they drink, and the places where they live.”   More than 2,400 years ago, Hippocrates transformed medicine by arguing that disease had natural—not supernatural—causes. His emphasis on clinical observation, ethics, prognosis, professionalism, and compassionate care laid the foundation for modern medicine.   The Hippocratic Oath remains one of the most enduring ethical pledges in human history. 📜✨   A timeless reminder that great medicine begins not only with...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

💊 Can weight loss achieved with injectable GLP-1 therapies be maintained using an oral agent?   The ATTAIN-MAINTAIN phase 3b trial published in Nature Medicine evaluated once-daily oral orforglipron after prior tirzepatide or semaglutide therapy. Patients maintained substantially more prior weight reduction versus placebo over 52 weeks, while preserving cardiometabolic benefits. 🌍⚖️   A fascinating glimpse into the future of scalable obesity care: oral incretin therapy may improve adherence, accessibility, and long-term maintenance.   #Obesity #GLP1 #Orforglipron...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

👁️ New NEJM correspondence highlights a potentially important ophthalmic signal linked to dulaglutide therapy. Two patients developed choroidal lymphoid hyperplasia with painless visual loss within months of GLP-1 receptor agonist initiation. Remarkably, ocular and systemic findings rapidly resolved after stopping dulaglutide. As GLP-1 therapies expand across diabetes, obesity, and cardiometabolic medicine, clinicians should remain vigilant for emerging ocular adverse events. A fascinating intersection of endocrinology, immunology, and ophthalmology. 🔬💉👓 #NEJM #GLP1 #Dulaglutide...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🫀 Scar. Signal. Survival.   A major new JAMA study from the NHLBI Hypertrophic Cardiomyopathy Registry followed 2,698 patients for nearly 7 years and demonstrated that advanced cardiac magnetic resonance imaging and NT-proBNP markedly improve prediction of adverse outcomes in hypertrophic cardiomyopathy.   📌 Key findings: • Late gadolinium enhancement (fibrosis burden) strongly predicted events • LGE ≥9% of LV mass substantially increased risk • LV mass index, LV systolic dysfunction, and NT-proBNP independently predicted outcomes • Traditional markers alone may miss...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🧠 Six landmark stroke investigations published in NEJM, JAMA, and Lancet are redefining modern reperfusion science.   🔹 ORIENTAL-MeVO: Thrombectomy improved outcomes in selected medium-vessel occlusion strokes. 🔹 TNK-PLUS: Bridging tenecteplase before EVT in the late window showed no added benefit. 🔹 CHOICE-2: Intra-arterial alteplase after successful thrombectomy improved excellent recovery but raised mortality concerns. 🔹 INSTANT: Early tirofiban after inadequate tenecteplase response improved 90-day outcomes. 🔹 TAPIS: Early ticagrelor + aspirin after thrombolysis...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

😴🧠 How much sleep is “just right” for healthy ageing? A remarkable Nature study of ~500,000 UK Biobank participants demonstrated a striking U-shaped relationship between sleep duration and biological ageing across 23 ageing clocks, 17 organs, and 3 omics platforms. 🌙🧬 Both short (<6 h) and long (>8 h) sleep were associated with accelerated ageing, higher systemic disease burden, and increased all-cause mortality. The biologic “sweet spot” appeared to be ~6–8 hours/night. ⏳❤️ An elegant reminder that sleep is not passive rest — it is active systemic repair....

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🫀 Old drug. New evidence. Renewed relevance. Two major JAMA studies published in 2026 revisit the role of digoxin/digitalis glycosides in modern cardiovascular care. 📊 A meta-analysis of 9,013 patients with HFmrEF/HFrEF showed reduced worsening heart failure events without increased mortality. 🌍 The Dig-RHD randomized trial from India demonstrated that digoxin reduced death or worsening heart failure in symptomatic rheumatic heart disease with minimal toxicity. Key message: 💊 Digoxin may still have an important role as affordable adjunctive therapy—especially in resource-limited...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🐍⚕️ Before modern hospitals, there were the healing temples of Asclepius — where medicine, ritual, dreams, and compassion converged.   Son of Apollo, trained by the wise centaur Chiron, Asclepius became the enduring symbol of healing in Greek civilization. His daughters — Hygieia, Panacea, and Iaso — represented health, cure, and recovery itself.   Even today, the Rod of Asclepius remains the universal emblem of medicine. 🌿   A reminder that the art of healing has always been more than science alone — it is wisdom, empathy, and hope.

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🧬 Predict. Prevent. Protect: The APOL1 Proteomic Revolution A fascinating new study in Nature Medicine describes a 9-protein APOL1 Proteomic Risk Score (APRS) capable of predicting kidney disease progression years before chronic kidney disease becomes clinically apparent. Among individuals of African ancestry with APOL1 high-risk genotypes and preserved kidney function, APRS achieved a remarkable time-dependent AUC of ~86%, substantially outperforming traditional clinical scores and polygenic risk tools. This work moves us closer to precision nephrology: identifying who is truly at risk,...

Dr. RR Baliga's 'Podkast for the Kurious Doc'. Where Curiosity meets Clarity!

🧠🎙️ New infographic from Dr RR Baliga’s Podkast for the Kurious Doc: “Colonoscopy, Cancer & Competing Risks.”   Two major 2026 studies from The Lancet and JAMA reshape how we think about colorectal cancer screening and surveillance.   🔹 The NordICC trial showed reduced colorectal cancer incidence with colonoscopy, but no significant mortality reduction after 13 years. 🔹 In adults ≥75 years with prior adenomas, non-colorectal cancer mortality far exceeded colorectal cancer risk, highlighting the importance of frailty and individualized decision-making.  ...